Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News FDA approves JNJ’s CAPLYTA for depression: Is this a new hope for MDD remission? Johnson & Johnson secures FDA approval for CAPLYTA in major depressive disorder. Find out how this expands safe treatment options for difficult-to-treat depression. bySrinathNovember 6, 2025